Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report

Zou,Fangwen; Xie,Guiyuan; Ma,Jin‑An; Zhou,Dong‑Ai; Jiang,Yi; Zheng,Jiao‑Yun

doi:10.3892/ol.2015.3057

Epidermal growth factor receptor mutation heterogeneity analysis of pulmonary sarcomatoid carcinoma successfully treated with erlotinib: A case report

Authors:
- Fangwen Zou
- Guiyuan Xie
- Jin‑An Ma
- Dong‑Ai Zhou
- Yi Jiang
- Jiao‑Yun Zheng
View Affiliations

Affiliations: Department of Oncology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China, Department of Pathology, The Second Xiangya Hospital of Central South University, Changsha, Hunan 410011, P.R. China
Published online on: March 18, 2015 https://doi.org/10.3892/ol.2015.3057
Pages: 2239-2243

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Pulmonary sarcomatoid carcinoma (PSC) is a rare histological subtype of non‑small cell lung cancer, and the available studies on the response to epidermal growth factor receptor tyrosine kinase inhibitors (EGFR‑TKIs) is limited. In the present study, a 73‑year‑old female presented with a large mass in the lower right lung, which was diagnosed as a PSC on biopsy. An amplification‑refractory mutation system (ARMS) test revealed that the patient possessed the wild‑type EGFR gene, and the patient subsequently underwent radiotherapy (60 Gy) and four 21‑day cycles of chemoradiotherapy (1,600 mg gemcitabine, days 1 and 8; 30 mg, cisplatin, days 1‑3). Following radiotherapy and chemotherapy treatment, a CT scan revealed complete remission of the mass in the lower right lung, however, metastases were identified in the paraaortic lymph node, bilateral iliac fossa and the right gluteal region. Notably, an EGFR exon 21 L858R gene mutation was identified in the mass of the right gluteal metastasis. Therefore, treatment with erlotinib was initiated. The patient continued to experience progression‑free survival for six months following the initiation of erlotinib therapy. However, multiple metastases were then identified, and all lesions possessed the wild‑type EGFR gene, as identified by the ARMS test. The findings suggest that erlotinib is a viable therapeutic option for the treatment of PSC patients that possess an EGFR mutation. The spatio‑temporal evolution of EGFR mutational heterogeneity in PSC may result in drug‑resistance, which challenges EGFR‑TKI therapy and EGFR gene mutation diagnosis.

View Figures

View References

1	Park JS, Lee Y, Han J, et al: Clinicopathologic outcomes of curative resection for sarcomatoid carcinoma of the lung. Oncology. 11:206–213. 2011. View Article : Google Scholar
2	Zhou Z, Jiang GN, Yang TS, et al: Analysis for the prognosis of patients with pulmonary carcinosarcoma. Zhong Guo Ai Zheng Za Zhi. 20:59–61. 2010.
3	Fishback NF, Travis WD, Moran CA, et al: Pleomorphic (spindle/giant cell) carcinoma of the lung. A clinicopathologic correlation of 78 cases. Cancer. 73:2936–2945. 1994. View Article : Google Scholar : PubMed/NCBI
4	Nakajima M, Kasai T, Hashimoto H, et al: Sarcomatoid carcinoma of the lung: a clinicopathologic study of 37 cases. Cancer. 86:608–616. 1999. View Article : Google Scholar : PubMed/NCBI
5	Beasley MB, Brambilla E and Travis WD: The 2004 World Health Organization classification of lung tumors. Semin Roentgenol. 40:90–97. 2005. View Article : Google Scholar : PubMed/NCBI
6	Venissac N, Pop D, Lassalle S, et al: Sarcomatoid lung cancer (spindle/giant cells): an aggressive disease? J Thorac Cardiovasc Surg. 134:619–623. 2007. View Article : Google Scholar : PubMed/NCBI
7	Brambilla E, Travis WD, Colby TV, Corrin B and Shimosato Y: The new World Health Organization classification of lung tumours. Eur Respir J. 18:1059–1068. 2001. View Article : Google Scholar : PubMed/NCBI
8	Homman T, Doki Y, Tsuda M, et al: Uncontrollable midbrain hemorrhage due to brain metastasis of pulmonary pleomorphic carcinoma. Kyobu Geka. 61:335–339. 2008.[(In Japanese)]. PubMed/NCBI
9	Petrov DB, Vlassov VI, Kalaydjiev GT, Plochev MA, Obretenov ED, Stanoev VI and Danon SE: Primary pulmonary sarcomas and carcinosarcomas - postoperative results and comparative survival analysis. Eur J Cardiothorac Surg. 23:461–466. 2003. View Article : Google Scholar : PubMed/NCBI
10	Shi YK: NCCN clinical practice guidelines in non-small cell lung cancer V.2.2008. Zhong Hua Zhong Liu Za Zhi. 30:397–400. 2008.
11	Italiano A, Cortot AB, Ilie M, et al: EGFR and KRAS status of primary sarcomatoid carcinomas of the lung: implications for anti-EGFR treatment of a rare lung malignancy. Int J Cancer. 125:2479–2482. 2009. View Article : Google Scholar : PubMed/NCBI
12	Leone A, Graziano P, Gasbarra R, et al: Identification of EGFR mutations in lung sarcomatoid carcinoma. Int J Cancer. 128:732–735. 2011. View Article : Google Scholar : PubMed/NCBI
13	Ushiki A, Koizumi T, Kobayashi N, et al: Genetic heterogeneity of EGFR mutation in pleomorphic carcinoma of the lung: response to gefitinib and clinical outcome. Jpn J Clin Oncol. 39:267–270. 2009. View Article : Google Scholar : PubMed/NCBI
14	Taniguchi K, Okami J, Kodama K, et al: Intratumor heterogeneity of epidermal growth factor receptor mutations in lung cancer and its correlation to the response to gefitinib. Cancer Sci. 99:929–935. 2008. View Article : Google Scholar : PubMed/NCBI
15	Tomonaga N, Nakamura Y, Yamaguchi H, et al: Analysis of intratumor heterogeneity of EGFR mutations in mixed-type lung adenocarcinoma. Clin Lung Cancer. 14:521–526. 2013. View Article : Google Scholar : PubMed/NCBI
16	Gow CH, Chang YL, Hsu YC, et al: Comparison of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in tyrosine kinase inhibitor-naive non-small-cell lung cancer. Ann Oncol. 20:696–702. 2009. View Article : Google Scholar : PubMed/NCBI
17	Schmid K, Oehl N, Wrba F, et al: EGFR/KRAS/BRAF mutations in primary lung adenocarcinomas and corresponding locoregional lymph node metastases. Clin Cancer Res. 15:4554–4560. 2009. View Article : Google Scholar : PubMed/NCBI
18	Sun L, Zhang Q, Luan H, et al: Comparison of KRAS and EGFR gene status between primary non-small cell lung cancer and local lymph node metastases: implications for clinical practice. J Exp Clin Cancer Res. 30:302011. View Article : Google Scholar : PubMed/NCBI
19	Fang Q, Zhang L, Wang S and Ou W: Discordance of epidermal growth factor receptor mutations between primary and corresponding metastatic tumors in non-small cell lung cancer. Zhongguo Fei Ai Za Zhi. 14:518–522. 2011.[(In Chinese)]. PubMed/NCBI
20	Gerlinger M, Rowan AJ, Horswell S, et al: Intratumor heterogeneity and branched evolution revealed by multiregion sequencing. N Engl J Med. 366:883–892. 2012. View Article : Google Scholar : PubMed/NCBI
21	Sequist LV, Waltman BA, Dias-Santagata D, et al: Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors. Sci Transl Med. 3:75ra262011. View Article : Google Scholar : PubMed/NCBI